Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert^® Bladder Cancer Monitor ) for surveillance in patients with non-muscle-invasive bladder cancer.

ABSTRACT:

Objective

To evaluate the performance of the Xpert Bladder Cancer Monitor (Xpert; Cepheid, Sunnyvale, CA, USA) test as a predictor of tumour recurrence in patients with non-muscle-invasive bladder cancer (NMIBC).

Patients and methods

Patients (n = 429) undergoing surveillance for NMIBC underwent Xpert, cytology, and UroVysion testing. Patients with a positive Xpert and a negative cystoscopy result (positive-negative [PN] group, n = 66) and a control group of double negative patients (negative Xpert and cystoscopy results [NN] group) were followed for 12 months (±90 days).

Results

Histology-confirmed recurrences were detected in 58 patients (13.5%). Xpert had an overall sensitivity of 60.3% and a specificity of 76.5%. The sensitivity for high-grade (HG) cancer was 87%

SUBMITTER: Cowan B 

PROVIDER: S-EPMC9292663 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature